Provided by Tiger Fintech (Singapore) Pte. Ltd.

Ocular Therapeutix

7.71
-0.1900-2.41%
Post-market: 7.710.00000.00%16:05 EDT
Volume:1.71M
Turnover:13.22M
Market Cap:1.23B
PE:-6.31
High:7.96
Open:7.79
Low:7.62
Close:7.90
Loading ...

Ocular Therapeutix™ to Report Fourth Quarter and Full Year 2024 Results on March 3, 2025

GlobeNewswire
·
24 Feb

Piper Sandler Sticks to Their Buy Rating for Ocular Therapeutix (OCUL)

TIPRANKS
·
10 Feb

Ocular Therapeutix reports inducement grant under Nasdaq listing rule

TIPRANKS
·
17 Jan

Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
17 Jan

Piper Sandler Keeps Their Buy Rating on Ocular Therapeutix (OCUL)

TIPRANKS
·
16 Jan

Ocular Therapeutix (OCUL) Gets a Buy from TD Cowen

TIPRANKS
·
15 Jan

Ocular Therapeutix Inc: Plans to Seek FDA Feedback in H1 2025 on Clinical Trial Design for Axpaxli in Npdr

THOMSON REUTERS
·
14 Jan

Ocular Therapeutix Inc: First Wet Amd Registrational Trial, Sol-1, Completed Randomization in December 2024 With Topline Data Anticipated in Q4 2025

THOMSON REUTERS
·
14 Jan

Ocular Therapeutix™ Shares Sol-R Enrollment Progress and Next Steps for Axpaxli™ in Npdr

THOMSON REUTERS
·
14 Jan

Investors push Ocular Therapeutix (NASDAQ:OCUL) 6.3% lower this week, company's increasing losses might be to blame

Simply Wall St.
·
11 Jan

Ocular Therapeutix™ to Provide Corporate Update During 43Rd Annual J.p. Morgan Healthcare Conference Presentation

THOMSON REUTERS
·
08 Jan

Ocular Therapeutix (OCUL) Receives a Buy from Bank of America Securities

TIPRANKS
·
07 Jan

Investors might be losing patience for Ocular Therapeutix's (NASDAQ:OCUL) increasing losses, as stock sheds 12% over the past week

Simply Wall St.
·
19 Dec 2024

Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
13 Dec 2024

Ocular Therapeutix announces over 300 subjects randomized in SOL-1

TipRanks
·
03 Dec 2024

Ocular Therapeutix Price Target Maintained With a $15.00/Share by HC Wainwright & Co.

Dow Jones
·
03 Dec 2024

Promising Outlook for Ocular Therapeutix: Buy Rating Supported by Strong Market Demand and Financial Valuation

TIPRANKS
·
03 Dec 2024

Ocular Therapeutix Inc -Topline Clinical Data From Sol-1 Expected in Q4 2025

THOMSON REUTERS
·
02 Dec 2024

Ocular Therapeutix Inc -Announces More Than 300 Subjects Randomized in Sol-1

THOMSON REUTERS
·
02 Dec 2024

Ocular Therapeutix (OCUL) Gets a Buy from Scotiabank

TIPRANKS
·
15 Nov 2024